Skip to content

Analgesic efficacy of intraperitoneal instillation of dexamethasone and bupivacaine versus bupivacaine in patient undergoing laparoscopic cholecystectomy.

Analgesic efficacy of intraperitoneal instillation of dexamethasone and bupivacaine versus bupivacaine in patient undergoing laparoscopic cholecystectomy.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079253
Enrollment
110
Registered
2025-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K800- Calculus of gallbladder with acutecholecystitis Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: DEXAMETHASONE AND BUPIVACAINE: Dexamethsone is the corticosteroids. it is commonly used in inflammatory conditions.Bupivacaine is a potent local anethesia drug. Hence in the study bupiv

Sponsors

JNMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to participate in the study ASA grade one to two. Patients undergoing laparoscopic cholecystectomy

Exclusion criteria

Exclusion criteria: Patients of age group less than eighteen years and above sixty years. ASA grade three to four. Patients with history of Diabetes mellitus. Patient allergic to the study drug. Pregnant females. Patients with history of previous abdominal surgeries. laparoscopic cholecystectomy got converted to open cholecystectomy. Patients on steroids.

Design outcomes

Primary

MeasureTime frame
patient receiving dexamethasone 12mg along with bupivacaine 0.25% 4o ml had a significantly longer duration of analgesiaTimepoint: Pre operatively and post operatively - baseline, 1 hourly, 2 hourly, 4 hourly, 8 hourly, 12 hourly, 16 hourly, 24 hourly

Secondary

MeasureTime frame
To compare the time of the first rescue. To compare the time to total rescue analgesic done. To study the post operative nausea,vomiting, hypergycemia and any adverse effect among the group.Timepoint: 24 hrs

Countries

India

Contacts

Public ContactNeeta Chaudhary Verma

Datta Meghe Institute of Medical Science and research

neetachaudhary1234@gmail.com8788378382

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026